Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09QZS
|
||||
| Former ID |
DNCL002598
|
||||
| Drug Name |
Olaratumab
|
||||
| Synonyms |
LY3012207
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Soft tissue sarcoma [ICD9: 171; ICD10:C00-D49] | Approved | [1] | ||
| Non-small cell lung cancer; Ovarian cancer [ICD9: 183; ICD10:C33-C34, C56] | Phase 1 | [2] | |||
| Company |
Eli Lilly
|
||||
| CAS Number |
CAS 1024603-93-7
|
||||
| Target and Pathway | |||||
| Target(s) | Alpha platelet-derived growth factor receptor | Target Info | Modulator | [3] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Ras signaling pathway | |||||
| Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Gap junction | |||||
| Regulation of actin cytoskeleton | |||||
| HTLV-I infection | |||||
| Pathways in cancer | |||||
| MicroRNAs in cancer | |||||
| Glioma | |||||
| Prostate cancer | |||||
| Melanoma | |||||
| Central carbon metabolism in cancer | |||||
| Choline metabolism in cancer | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| PDGF signaling pathway | |||||
| Pathway Interaction Database | ATF-2 transcription factor network | ||||
| PDGFR-alpha signaling pathway | |||||
| PDGF receptor signaling network | |||||
| Reactome | PIP3 activates AKT signaling | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| RAF/MAP kinase cascade | |||||
| WikiPathways | Regulation of Actin Cytoskeleton | ||||
| Osteoblast Signaling | |||||
| Focal Adhesion | |||||
| Hair Follicle Development: Organogenesis (Part 2 of 3) | |||||
| PIP3 activates AKT signaling | |||||
| Cardiac Progenitor Differentiation | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Allograft Rejection | |||||
| Signaling Pathways in Glioblastoma | |||||
| Signaling by PDGF | |||||
| Angiogenesis | |||||
| References | |||||
| REF 1 | 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. doi: 10.1038/nrd.2017.14. | ||||
| REF 2 | ClinicalTrials.gov (NCT02377752) A Study of Olaratumab in Japanese Participants With Advanced Cancer. U.S. National Institutes of Health. | ||||
| REF 3 | A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.